Cancer Research Communications

OCT 19, 2026 · JOURNAL ARTICLE

Paxalisib with Trastuzumab for HER2-Positive Metastatic Breast Cancer with Active Brain Metastases: A Phase II Trial with Integrated Plasma and CSF ctDNA Analyses

Cancer Research Communications

Abstract Purpose: HER2+ breast cancer brain metastases (BCBM) frequently harbor PI3K/AKT/mTOR alterations. Preclinical HER2+ BCBM models demonstrated durable tumor regression with

OCT 13, 2026 · JOURNAL ARTICLE

The use of TF-Ag-α to selectively capture tumor-derived extracellular vesicles and enhance the predictive performance of extracellular vesicle PD-L1 for response to immune checkpoint inhibitors

Cancer Research Communications

Abstract Only a subset of non-small cell lung cancer (NSCLC) patients benefits from immune checkpoint inhibitors (ICIs). Tissue PD-L1 has limited accuracy in predicting ICI respons

OCT 12, 2026 · JOURNAL ARTICLE

Nicotinic acid restriction potentiates NAMPT inhibition in acute myeloid leukemia xenograft models.

Cancer Research Communications

Abstract NAMPT, a key enzyme in NAD biosynthesis, is a potential therapeutic target in cancer. Acute myeloid leukemia (AML) is among cancer types exhibiting high NAMPT dependence,

OCT 7, 2026 · JOURNAL ARTICLE

ERX 208 induces endoplasmic reticulum stress and suppresses DNA damage repair to enhance chemotherapy sensitivity

Cancer Research Communications

Abstract Ovarian cancer (OCa) remains the most lethal gynecologic malignancy, driven in part by intrinsic and acquired therapeutic resistance to DNA damaging chemotherapies. We pre

SEP 29, 2026 · JOURNAL ARTICLE

Auranofin potentiates cisplatin response in the setting of context-dependent NOTCH-associated signaling states in endometrial cancer

Cancer Research Communications

Abstract Therapeutic resistance remains a major challenge in advanced and recurrent endometrial cancer (EC). Aberrant NOTCH signaling has been associated with aggressive tumor beha

SEP 29, 2026 · JOURNAL ARTICLE

Clinical and Molecular Profiles of Treatment-Emergent Small Cell Neuroendocrine Prostate Cancers in the Era of Intensified Systemic Therapies

Cancer Research Communications

Abstract Variant histologic features can emerge in therapy-resistant prostate cancers, with treatment-emergent small-cell neuroendocrine carcinomas (t-SCNC) the most common. Here w

SEP 21, 2026 · JOURNAL ARTICLE

Integrated genetic screening identifies FEN1 as a selective vulnerability and temozolomide resistance mediator in glioblastoma stem cells

Cancer Research Communications

Abstract Glioblastoma (GBM) is an aggressive brain tumor characterized by therapy resistance and recurrence. Glioblastoma stem cells (GSCs) are key drivers of tumor maintenance, th

SEP 4, 2026 · JOURNAL ARTICLE

A Phase 1 Study of PF-07062119, an Anti-GUCY2C/Anti-CD3 Bispecific Fc Antibody, in Patients With Advanced Gastrointestinal Cancers

Cancer Research Communications

First-in-human Phase 1 dose escalation with primary focus on safety and tolerability; anti-tumor activity is secondary and minimal (2.5% ORR), consistent with early-phase exploratory work.